Cargando…

Antihypertensive efficacy of metoprolol XL/Low dose chlorthalidone (6.25 mg) combination: a randomized, comparative study in Indian patients with mild-to-moderate essential hypertension

OBJECTIVE: High blood pressure is one of the most important risk factors, directly responsible for increasing the cardiovascular morbidity and mortality. The primary objective was to evaluate the efficacy of metoprolol XL/chlorthalidone against metoprolol XL/hydrochlorothiazide with respect to mean...

Descripción completa

Detalles Bibliográficos
Autores principales: Pareek, A, Zawar, SD, Salagre, SB, Chandurkar, NB, Karnik, ND
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3458640/
https://www.ncbi.nlm.nih.gov/pubmed/19661012
http://dx.doi.org/10.1186/2047-783X-14-7-297
_version_ 1782244683391434752
author Pareek, A
Zawar, SD
Salagre, SB
Chandurkar, NB
Karnik, ND
author_facet Pareek, A
Zawar, SD
Salagre, SB
Chandurkar, NB
Karnik, ND
author_sort Pareek, A
collection PubMed
description OBJECTIVE: High blood pressure is one of the most important risk factors, directly responsible for increasing the cardiovascular morbidity and mortality. The primary objective was to evaluate the efficacy of metoprolol XL/chlorthalidone against metoprolol XL/hydrochlorothiazide with respect to mean fall in systolic and diastolic blood pressure. The secondary objective was to compare the response rates and to evaluate the tolerability of study medications in patients with mild-tomoderate essential hypertension. METHODS: Total 130 eligible patients (65: metoprolol XL 25 mg/chlorthalidone 6.25 mg; 65: metoprolol XL 25 mg/HCTZ 12.5 mg) were enrolled in this randomized, comparative, multicentric, 12-weeks study. Sixty-two patients from each group completed the study. After 4-weeks of treatment, non-responders from chlorthalidone 6.25 mg combination group were shifted to metoprolol XL 50 mg/chlorthalidone 12.5 mg and non-responders from HCTZ 12.5 mg combination group were escalated to metoprolol XL 50 mg/HCTZ 12.5 mg. RESULTS: The study treatment groups were comparable with respect to demography and baseline disease characteristics. Both the starting therapies were comparable with respect to mean fall in SBP (p = 0.788) and DBP (p = 0.939), and response rates (p = 1.0) after 4-weeks of therapy. Also both the step-up therapies showed similar mean fall in SBP (p = 0.277) and DBP (p = 0.507) at the end of 12-weeks. However, significantly more number of patients from chlorthalidone 12.5 mg/metoprolol XL 50 mg group responded to therapy as compared to that from HCTZ 12.5 mg/metoprolol XL 50 mg group (p = 0.045). All the reported adverse events were of mild-to-moderate intensity. There were no clinically significant trends in electrolytes (Na(+), K(+), Cl(-))and fasting blood sugar, evident across the treatment groups. CONCLUSION: Chlorthalidone in combination with metoprolol XL is as effective and well tolerated as widely used combination of metoprolol XL/HCTZ, thus providing an alternative therapeutic option.
format Online
Article
Text
id pubmed-3458640
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34586402012-09-27 Antihypertensive efficacy of metoprolol XL/Low dose chlorthalidone (6.25 mg) combination: a randomized, comparative study in Indian patients with mild-to-moderate essential hypertension Pareek, A Zawar, SD Salagre, SB Chandurkar, NB Karnik, ND Eur J Med Res Research OBJECTIVE: High blood pressure is one of the most important risk factors, directly responsible for increasing the cardiovascular morbidity and mortality. The primary objective was to evaluate the efficacy of metoprolol XL/chlorthalidone against metoprolol XL/hydrochlorothiazide with respect to mean fall in systolic and diastolic blood pressure. The secondary objective was to compare the response rates and to evaluate the tolerability of study medications in patients with mild-tomoderate essential hypertension. METHODS: Total 130 eligible patients (65: metoprolol XL 25 mg/chlorthalidone 6.25 mg; 65: metoprolol XL 25 mg/HCTZ 12.5 mg) were enrolled in this randomized, comparative, multicentric, 12-weeks study. Sixty-two patients from each group completed the study. After 4-weeks of treatment, non-responders from chlorthalidone 6.25 mg combination group were shifted to metoprolol XL 50 mg/chlorthalidone 12.5 mg and non-responders from HCTZ 12.5 mg combination group were escalated to metoprolol XL 50 mg/HCTZ 12.5 mg. RESULTS: The study treatment groups were comparable with respect to demography and baseline disease characteristics. Both the starting therapies were comparable with respect to mean fall in SBP (p = 0.788) and DBP (p = 0.939), and response rates (p = 1.0) after 4-weeks of therapy. Also both the step-up therapies showed similar mean fall in SBP (p = 0.277) and DBP (p = 0.507) at the end of 12-weeks. However, significantly more number of patients from chlorthalidone 12.5 mg/metoprolol XL 50 mg group responded to therapy as compared to that from HCTZ 12.5 mg/metoprolol XL 50 mg group (p = 0.045). All the reported adverse events were of mild-to-moderate intensity. There were no clinically significant trends in electrolytes (Na(+), K(+), Cl(-))and fasting blood sugar, evident across the treatment groups. CONCLUSION: Chlorthalidone in combination with metoprolol XL is as effective and well tolerated as widely used combination of metoprolol XL/HCTZ, thus providing an alternative therapeutic option. BioMed Central 2009-07-22 /pmc/articles/PMC3458640/ /pubmed/19661012 http://dx.doi.org/10.1186/2047-783X-14-7-297 Text en Copyright ©2009 I. Holzapfel Publishers
spellingShingle Research
Pareek, A
Zawar, SD
Salagre, SB
Chandurkar, NB
Karnik, ND
Antihypertensive efficacy of metoprolol XL/Low dose chlorthalidone (6.25 mg) combination: a randomized, comparative study in Indian patients with mild-to-moderate essential hypertension
title Antihypertensive efficacy of metoprolol XL/Low dose chlorthalidone (6.25 mg) combination: a randomized, comparative study in Indian patients with mild-to-moderate essential hypertension
title_full Antihypertensive efficacy of metoprolol XL/Low dose chlorthalidone (6.25 mg) combination: a randomized, comparative study in Indian patients with mild-to-moderate essential hypertension
title_fullStr Antihypertensive efficacy of metoprolol XL/Low dose chlorthalidone (6.25 mg) combination: a randomized, comparative study in Indian patients with mild-to-moderate essential hypertension
title_full_unstemmed Antihypertensive efficacy of metoprolol XL/Low dose chlorthalidone (6.25 mg) combination: a randomized, comparative study in Indian patients with mild-to-moderate essential hypertension
title_short Antihypertensive efficacy of metoprolol XL/Low dose chlorthalidone (6.25 mg) combination: a randomized, comparative study in Indian patients with mild-to-moderate essential hypertension
title_sort antihypertensive efficacy of metoprolol xl/low dose chlorthalidone (6.25 mg) combination: a randomized, comparative study in indian patients with mild-to-moderate essential hypertension
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3458640/
https://www.ncbi.nlm.nih.gov/pubmed/19661012
http://dx.doi.org/10.1186/2047-783X-14-7-297
work_keys_str_mv AT pareeka antihypertensiveefficacyofmetoprololxllowdosechlorthalidone625mgcombinationarandomizedcomparativestudyinindianpatientswithmildtomoderateessentialhypertension
AT zawarsd antihypertensiveefficacyofmetoprololxllowdosechlorthalidone625mgcombinationarandomizedcomparativestudyinindianpatientswithmildtomoderateessentialhypertension
AT salagresb antihypertensiveefficacyofmetoprololxllowdosechlorthalidone625mgcombinationarandomizedcomparativestudyinindianpatientswithmildtomoderateessentialhypertension
AT chandurkarnb antihypertensiveefficacyofmetoprololxllowdosechlorthalidone625mgcombinationarandomizedcomparativestudyinindianpatientswithmildtomoderateessentialhypertension
AT karniknd antihypertensiveefficacyofmetoprololxllowdosechlorthalidone625mgcombinationarandomizedcomparativestudyinindianpatientswithmildtomoderateessentialhypertension